Thalidomide and Dexamethasone for Multiple Myeloma
Author Information
Author(s): Marie von Lilienfeld-Toal, Corinna Hahn-Ast, Kerstin Furkert, Florian Hoffmann, Ralph Naumann, Ralf Bargou, Gordon Cook, Axel Glasmacher
Primary Institution: Medizinische Klinik und Poliklinik III, Rheinische Friedrich Wilhelms Universität Bonn, Germany
Hypothesis
Does the combination of thalidomide and dexamethasone improve response rates and increase adverse events in patients with relapsed or refractory multiple myeloma?
Conclusion
The combination of thalidomide and dexamethasone improves response rates in relapsed/refractory multiple myeloma without significantly increasing toxicity.
Supporting Evidence
- The response rate for thalidomide monotherapy is 30%, while the combination therapy shows a response rate of 46%.
- Therapy-related toxicity was comparable to thalidomide monotherapy.
- Common adverse events included somnolence (26%), constipation (37%), and peripheral neuropathy (27%).
- Venous thromboembolism occurred more frequently with the combination therapy at a rate of 5%.
Takeaway
This study shows that using thalidomide with another medicine called dexamethasone helps more people with a type of blood cancer called multiple myeloma feel better, and it doesn't make them much sicker.
Methodology
A systematic review of 12 studies evaluating the efficacy and toxicity of thalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Potential Biases
Potential reporting bias in adverse events due to inconsistencies in study reporting.
Limitations
The studies included were mostly unicentric phase II studies and none were randomized controlled trials.
Participant Demographics
Median age of participants was 63 years, with most having relapsed disease.
Statistical Information
P-Value
0.016
Confidence Interval
95% CI 42–51%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website